Results 51 to 60 of about 3,125,328 (279)

Elevated-c-MYC-expressing Fibrosarcoma Cells With Acquired Gemcitabine Resistance Remain Sensitive to Recombinant Methioninase: A Potential Clinical Strategy for a Recalcitrant Disease. [PDF]

Cancer Diagn Progn
Morinaga S, Han Q, Mizuta K, Kang BM, Bouvet M, Yamamoto N, Hayashi K, Kimura H, Miwa S, Igarashi K, Higuchi T, Tsuchiya H, Demura S, Hoffman RM.   +13 more
europepmc   +3 more sources

Saikosaponin D reverses epinephrine- and norepinephrine-induced gemcitabine resistance in intrahepatic cholangiocarcinoma by downregulating ADRB2/glycolysis signaling

Acta Biochimica et Biophysica Sinica, 2023
Intrahepatic cholangiocarcinoma (iCCA) is a highly fatal malignancy with rapidly increasing incidence and mortality worldwide. Currently, gemcitabine-based systemic chemotherapy is the main clinical therapeutic regimen; however, its efficacy is poor, and
Hui He, Jiaqi Guo, Yunxiang Hu, Han Zhang, Xinyang Li, Jian Zhang, Shi Jin   +6 more
semanticscholar   +1 more source

Gemcitabine-induced Gli-dependent activation of hedgehog pathway resists to the treatment of urothelial carcinoma cells.

PLoS ONE, 2021
Patients with urothelial carcinoma (UC) experience gemcitabine resistance is a critical issue. The role of hedgehog pathway in the problem was explored.
Yu-Hao Chang, Hoi-Lam Tam, Meng-Chien Lu, Huei-Sheng Huang   +3 more
doaj   +1 more source

circFARP1 enables cancer-associated fibroblasts to promote gemcitabine resistance in pancreatic cancer via the LIF/STAT3 axis

Molecular Cancer, 2022
Background Cancer-associated fibroblasts (CAFs) are critically involved in gemcitabine (GEM) resistance in pancreatic ductal adenocarcinoma (PDAC). However, the underlying mechanism by which CAFs promote chemotherapy resistance remains unexplored.
Chonghui Hu, Renpeng Xia, Xiang Zhang, Tingting Li, Yuancheng Ye, Guolin Li, Rihua He, Zhihua Li, Qing Lin, Shangyou Zheng, Rufu Chen   +10 more
semanticscholar   +1 more source

MYC/glutamine dependency is a therapeutic vulnerability in pancreatic cancer with deoxycytidine kinase inactivation-induced gemcitabine resistance.

Molecular Cancer Research, 2023
Pancreatic ductal adenocarcinoma (PDAC) is one of the most life-threatening malignancies. Although the deoxycytidine analog gemcitabine has been used as the first-line treatment for PDAC, the primary clinical challenge arises because of an eventual ...
Santanu Kumar Dash, Takeshi Ueda, A. Komuro, H. Amano, Masahiko Honda, Masahito Kawazu, H. Okada   +6 more
semanticscholar   +1 more source

LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway

Cancer Research, 2021
These findings show that a reciprocal feedback of HIF1A-AS1 and HIF1α promotes gemcitabine resistance of pancreatic cancer, which provides an applicable therapeutic target.
Feng-yu Xu, Mengqi Huang, Qing-yong Chen, Y. Niu, Yuhang Hu, Ping Hu, Ding Chen, Chi He, Kang Huang, Zhu Zeng, Jiang Tang, Fan Wang, Yong Zhao, Chun-you Wang, Gang Zhao   +14 more
semanticscholar   +1 more source

m6A Methyltransferase METTL14-Mediated Upregulation of Cytidine Deaminase Promoting Gemcitabine Resistance in Pancreatic Cancer

Frontiers in Oncology, 2021
ObjectivePancreatic cancer is one of the most lethal human malignancies. Gemcitabine is widely used to treat pancreatic cancer, and the resistance to chemotherapy is the major difficulty in treating the disease.
Congjun Zhang, Shuangyan Ou, Yuan Zhou, Pei Liu, Peiying Zhang, Ziqian Li, Ruocai Xu, Yuqiang Li   +7 more
doaj   +1 more source

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

Hepatology, EarlyView., 2022
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou, Yongkun Sun, Wen Zhang, Jiajia Yuan, Zhi Peng, Wei Wang, Jifang Gong, Lin Yang, Yanshuo Cao, Hong Zhao, Chao Chen, Weifeng Wang, Lin Shen, Aiping Zhou   +13 more
wiley   +1 more source

SLC39A1 contributes to gemcitabine resistance of pancreatic ductal adenocarcinoma by activating AMPK signaling

Bangladesh Journal of Pharmacology
Gemcitabine is a common first-line chemotherapy agent, but gemcitabine resistance is a clinical challenge for pancreatic ductal adenocarcinoma patients.
Hao Yu, Xiaoping Mei, Xueming Zhang, Neng Qian, Qingjiang Yu, Hongkun Zhou   +5 more
doaj   +1 more source

UPP1 enhances bladder cancer progression and gemcitabine resistance through AKT

International Journal on Biological Sciences
UPP1, a crucial pyrimidine metabolism-related enzyme, catalyzes the reversible phosphorylation of uridine to uracil and ribose-1-phosphate. However, the effects of UPP1 in bladder cancer (BLCA) have not been elucidated.
Wenzhi Du, Sheng Tu, Wenxiu Zhang, Yi Zhang, Wei Liu, Kangping Xiong, Fen-fang Zhou, Na Li, Renjie Zhang, Jingtian Yu, Mingxing Li, Wan Xiang, Kaiyu Qian, Gang Wang, Yu Xiao, Xinghuan Wang, Lingao Ju   +16 more
semanticscholar   +1 more source